ClinicalTrials.gg
CompletedNCT02643420ADVANCEUpdated Mar 2, 2022Results posted

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

A Phase 3 interventional study of SPI-2012 and Pegfilgrastim in Neutropenia and Breast Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 81 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
4th of 28
406 · median 121
Started
2016
the only one that year
Phase 3
11 of 33
none open now
Registered
29th of 33
by date
Lead sponsor
3 of 33
Spectrum Pharmaceuticals, Inc

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2016, is one of 11 in phase 3, and was the 29th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.

Read the detailed description

This was a Phase 3, randomized, open-label, active-controlled, multicenter study to compare the efficacy and safety of SPI-2012 vs pegfilgrastim in participants with breast cancer treated with TC chemotherapy.

Each cycle was 21 days. Four cycles were evaluated in this study. On Day 1 of each cycle, participants received TC chemotherapy. On Day 2 of each cycle, participants received study drug (SPI-2012 or pegfilgrastim).

03

Conditions studied

  • Neutropenia
  • Breast Cancer

Keywords

  • Neutropenia
  • Breast Cancer
  • Long-acting Myeloid Growth Factor
  • Early Stage Breast Cancer
  • Docetaxel + Cyclophosphamide (TC) chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • New diagnosis of confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer
  • Candidate for or neoadjuvant TC chemotherapy
  • (ECOG) performance score ≤ 2
  • (ANC) ≥ 1.5×10\^9/L
  • count ≥ 100×10\^9/L
  • > 9 g/dL
  • > 50 mL/min
  • Total ≤ 1.5 mg/dL
  • per Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase per Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5× (ULN).
  • Alkaline phosphatase ≤ 2.0×ULN

Key Exclusion Criteria:

  • Active concurrent (except non-melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease
  • Locally recurrent or breast cancer
  • Known sensitivity to E. coli -derived products or to any products to be administered during dosing
  • Concurrent adjuvant cancer therapy
  • Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug
  • Active infection, receiving anti-infectives, or any serious underlying medical condition that would impair ability to receive protocol treatment
  • Prior bone marrow or stem cell transplant
  • Use of any drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study
  • Radiation therapy within 30 days prior to enrollment
  • Major surgery within 30 days prior to enrollment
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)

    Participants received SPI-2012 13.2 milligram (mg)/0.6 milliliter (mL) (3.6 mg Granulocyte Colony-Stimulating Factor \[G-CSF\]) fixed-dose subcutaneous (SC) injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy was administered on Day 1 of each cycle and included Docetaxel 75 mg/m\^2 intravenous (IV) infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.

    Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide

  • Experimental
    Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)

    Participants received pegfilgrastim 6 mg SC injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy on Day 1 of each cycle included Docetaxel 75 mg/m\^2 IV infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.

    Drug: Pegfilgrastim · Drug: Docetaxel · Drug: Cyclophosphamide

Interventions

  • DrugEflapegrastimStudies of EflapegrastimEflapegrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle

    Also known as: Rolontis®, Eflapegrastim, (HM10460A)

  • Single-dose subcutaneous injection administered on Day 2 of each cycle

    Also known as: Neulasta®

  • Standard therapy

    Also known as: Taxotere

  • Standard therapy

    Also known as: Cytoxan

06

What researchers measure

Primary outcomes

  1. Duration of Severe Neutropenia (DSN) in Cycle 1

    DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9/L), after the administration of study drug in Cycle 1.

    Time frame: Day 1 and Days 4-15 in Cycle 1 (each cycle was 21 days)

Secondary outcomes

  1. Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1

    Time to ANC Recovery was defined as the time from chemotherapy administration until ANC increased to ≥1.5×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was assigned as 0 for participants whose ANC value never dropped below 1.5 x10\^9/L.

    Time frame: Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)

  2. Depth of Absolute Neutrophil Count (ANC) Nadir in Cycle 1

    Depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or Pegfilgrastim) in Cycle 1.

    Time frame: Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)

  3. Number of Participants With Febrile Neutropenia (FN) in Cycle 1

    FN was defined as an oral temperature \> 38.3 degrees Celsius (C) (101.0 degrees Fahrenheit \[F\]) or two consecutive readings of \>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \<1.0×10\^9/L.

    Time frame: Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)

  4. Duration of Severe Neutropenia in Cycle 2, 3 and 4

    DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9 /L) from the first occurrence of an ANC below the threshold in Cycles 2, 3, and 4.

    Time frame: Days 1, 4, 7, 10, and 15 in cycles 2, 3, and 4 (each cycle was 21 days)

  5. Number of Participants With Neutropenic Complications in Cycle 1

    Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.

    Time frame: Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)

  6. Number of Participants With Febrile Neutropenia in Cycles 2, 3, and 4

    FN was defined as an oral temperature \> 38.3 degrees C (101.0 degrees Fahrenheit \[F\]) or two consecutive readings of \>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \<1.0×10\^9/L.

    Time frame: Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle was 21 days)

  7. Relative Dose Intensity (RDI) of TC (Docetaxel + Cyclophosphamide) in Cycles 1 to 4

    RDI was defined as the percentage of the planned dose that each participant actually received during the study, expressed as the total dose received, divided by the total dose planned and multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.

    Time frame: Cycles 1 to 4 (each cycle was 21 days)

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE for Treatment Period is defined as adverse event with an onset date on or after the date of study drug administration through the end of treatment. TEAE for follow up is defined as any new onset or ongoing AE at the end of Treatment. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.

    Time frame: From the first dose of TC (Docetaxel + Cyclophosphamide) until 12 months after the last dose of study treatment (up to approximately 34 months)

07

Results

Posted Mar 2, 2022

Participant flow

Participants were enrolled from 19 Jan 2016 to 31 Oct 2018. A total of 406 participants were randomized in the study.

Participant flow — Overall Study
MilestoneArm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)
Started196210
Safety population197208
Completed142145
Not completed5465
Withdrew: Initiation of non-protocol therapy for breast cancer612
Withdrew: Withdrawal by subject2519
Withdrew: Treatment with additional myeloid growth factors during follow-up610
Withdrew: Lost to follow-up610
Withdrew: Investigator decision24
Withdrew: Sponsor decision11
Withdrew: Death02
Withdrew: Reason not specified87

Outcome measures

PrimaryDuration of Severe Neutropenia (DSN) in Cycle 1

DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9/L), after the administration of study drug in Cycle 1.

Time frame:
Day 1 and Days 4-15 in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · days
Duration of Severe Neutropenia (DSN) in Cycle 1
daysArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Duration of Severe Neutropenia (DSN) in Cycle 10.20 ± 0.5030.35 ± 0.683
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · t-statistics · p = <0.0001 · Mean difference (final values): -0.148 · 95% CI -0.266 to -0.031The p-values are based on the calculated t-statistics from the bootstrapped sample mean and standard deviation.
SecondaryTime to Absolute Neutrophil Count (ANC) Recovery in Cycle 1

Time to ANC Recovery was defined as the time from chemotherapy administration until ANC increased to ≥1.5×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was assigned as 0 for participants whose ANC value never dropped below 1.5 x10\^9/L.

Time frame:
Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · days
Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1
daysArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 13.24 ± 3.5653.49 ± 3.589
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Negative binomial regression · p = 0.685 · Mean difference (final values): -0.25 · 95% CI -1.43 to 0.94
SecondaryDepth of Absolute Neutrophil Count (ANC) Nadir in Cycle 1

Depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or Pegfilgrastim) in Cycle 1.

Time frame:
Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)
Reported as:
Mean · 10^9 ANC/L
Depth of Absolute Neutrophil Count (ANC) Nadir in Cycle 1
10^9 ANC/LArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Depth of Absolute Neutrophil Count (ANC) Nadir in Cycle 12.56 ± 3.0862.53 ± 3.317
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Asymptotic normality assumption · p = 0.155 · Median difference (final values): 1.2 · 95% CI 0.93 to 1.56P-value was obtained based upon asymptotic normality assumption on the log10 transformed data.
SecondaryNumber of Participants With Febrile Neutropenia (FN) in Cycle 1

FN was defined as an oral temperature \> 38.3 degrees Celsius (C) (101.0 degrees Fahrenheit \[F\]) or two consecutive readings of \>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \<1.0×10\^9/L.

Time frame:
Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia (FN) in Cycle 1
ParticipantsArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Number of Participants With Febrile Neutropenia (FN) in Cycle 142
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Fisher Exact · p = 0.435 · Percent difference: 1.1 · 95% CI -8.6 to 10.8
SecondaryDuration of Severe Neutropenia in Cycle 2, 3 and 4

DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9 /L) from the first occurrence of an ANC below the threshold in Cycles 2, 3, and 4.

Time frame:
Days 1, 4, 7, 10, and 15 in cycles 2, 3, and 4 (each cycle was 21 days)
Reported as:
Mean · days
Duration of Severe Neutropenia in Cycle 2, 3 and 4
daysArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Cycle 20.13 ± 0.3830.09 ± 0.374
Cycle 30.11 ± 0.3260.08 ± 0.273
Cycle 40.11 ± 0.3620.09 ± 0.281
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · t-statistics · p = <0.0001 · Mean difference (final values): 0.042 · 95% CI -0.032 to 0.116
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · t-statistics · p = <0.0001 · Mean difference (final values): 0.026 · 95% CI -0.032 to 0.085
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · t-statistics · p = <0.0001 · Mean difference (final values): 0.027 · 95% CI -0.036 to 0.089
SecondaryNumber of Participants With Neutropenic Complications in Cycle 1

Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.

Time frame:
Day 1 and Days 4, 15 in Cycle 1 (each cycle was 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Neutropenic Complications in Cycle 1
ParticipantsArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Number of Participants With Neutropenic Complications in Cycle 188
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Fisher Exact · p = 1.000 · Percent difference: 0.3 · 95% CI -9.5 to 10.0
SecondaryNumber of Participants With Febrile Neutropenia in Cycles 2, 3, and 4

FN was defined as an oral temperature \> 38.3 degrees C (101.0 degrees Fahrenheit \[F\]) or two consecutive readings of \>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \<1.0×10\^9/L.

Time frame:
Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle was 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia in Cycles 2, 3, and 4
ParticipantsArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Cycle 211
Cycle 341
Cycle 420
Statistical analysis
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Fisher Exact · p = 1.000 · Percent difference: 0.0 · 95% CI -9.7 to 9.8
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Fisher Exact · p = 0.201 · Percent difference: 1.6 · 95% CI -8.2 to 11.3
  • Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC · Fisher Exact · p = 0.232 · Percent difference: 1.0 · 95% CI -8.7 to 10.8
SecondaryRelative Dose Intensity (RDI) of TC (Docetaxel + Cyclophosphamide) in Cycles 1 to 4

RDI was defined as the percentage of the planned dose that each participant actually received during the study, expressed as the total dose received, divided by the total dose planned and multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.

Time frame:
Cycles 1 to 4 (each cycle was 21 days)
Reported as:
Mean · percentage of planned dose
Relative Dose Intensity (RDI) of TC (Docetaxel + Cyclophosphamide) in Cycles 1 to 4
percentage of planned doseArm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TC
Docetaxel99.1 ± 5.4798.1 ± 8.45
Cyclophosphamide99.3 ± 3.8699.0 ± 4.33
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE for Treatment Period is defined as adverse event with an onset date on or after the date of study drug administration through the end of treatment. TEAE for follow up is defined as any new onset or ongoing AE at the end of Treatment. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.

Time frame:
From the first dose of TC (Docetaxel + Cyclophosphamide) until 12 months after the last dose of study treatment (up to approximately 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsArm 1: SPI-2012 and TC -Treatment PeriodArm 2: Pegfilgrastim and TC -Treatment PeriodArm 1: SPI-2012 and TC - Follow up PeriodArm 2: Pegfilgrastim and TC - Follow up Period
TEAE1922049583
SAE362982

Adverse events

Collected over From the first dose of TC (Docetaxel + Cyclophosphamide) until 12 months after the last dose of study treatment (up to approximately 34 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: SPI-2012 and TC -Treatment Period0/197 (0%)36/197 (18.3%)192/197 (97.5%)
Arm 2: Pegfilgrastim and TC -Treatment Period1/208 (0.5%)29/208 (13.9%)203/208 (97.6%)
Arm 1: SPI-2012 and TC - Follow up Period0/197 (0%)8/197 (4.1%)92/197 (46.7%)
Arm 2: Pegfilgrastim and TC - Follow up Period1/208 (0.5%)2/208 (1%)82/208 (39.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventArm 1: SPI-2012 and TC -Treatment PeriodArm 2: Pegfilgrastim and TC -Treatment PeriodArm 1: SPI-2012 and TC - Follow up PeriodArm 2: Pegfilgrastim and TC - Follow up Period
PyrexiaGeneral disorders3/1976/2081/1970/208
Febrile neutropeniaBlood and lymphatic system disorders3/1972/2081/1970/208
VomitingGastrointestinal disorders0/1973/2080/1970/208
PneumoniaInfections and infestations2/1973/2080/1970/208
SepsisInfections and infestations2/1973/2080/1970/208
ColitisGastrointestinal disorders2/1970/2080/1970/208
DiarrhoeaGastrointestinal disorders2/1971/2080/1970/208
Chest painGeneral disorders2/1970/2080/1970/208
Colonic abscessInfections and infestations2/1970/2080/1970/208
DiverticulitisInfections and infestations2/1970/2080/1970/208
Most frequent other events
Showing 10 of 60
Most frequent other events
EventArm 1: SPI-2012 and TC -Treatment PeriodArm 2: Pegfilgrastim and TC -Treatment PeriodArm 1: SPI-2012 and TC - Follow up PeriodArm 2: Pegfilgrastim and TC - Follow up Period
FatigueGeneral disorders120/197124/20814/1978/208
NauseaGastrointestinal disorders112/197104/20811/1977/208
AlopeciaSkin and subcutaneous tissue disorders95/19793/2082/1971/208
DiarrhoeaGastrointestinal disorders87/19786/2083/1973/208
Lymphocyte count decreasedInvestigations80/19774/2082/1970/208
Bone painMusculoskeletal and connective tissue disorders71/19770/2086/1975/208
NeutropeniaBlood and lymphatic system disorders67/19765/2081/1971/208
ConstipationGastrointestinal disorders62/19748/2082/1972/208
HeadacheNervous system disorders59/19755/2085/1975/208
AnaemiaBlood and lymphatic system disorders51/19739/2083/1970/208

Baseline characteristics

The Intent to Treat (ITT) population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Arm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TCTotal
Mean59.9 ± 11.1259.0 ± 11.7959.5 ± 11.47
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TCTotal
Female195209404
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TCTotal
Hispanic or Latino344074
Not Hispanic or Latino162170332
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: SPI-2012 and TCArm 2: Pegfilgrastim and TCTotal
White or Caucasian156159315
Black or African American263258
Asian9918
American Indian or Alaska Native112
Native Hawaiian or Other Pacific Islander011
Other4812
08

Study locations

81 sites
  • Arizona Center for Cancer Care
    Glendale, Arizona 85306, United States
  • Arizona Clinical Research Center/ ACRC
    Tucson, Arizona 85715, United States
  • Yuma Regional Medical Center
    Yuma, Arizona 85364, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • NEA Baptist Clinic | Fowler Family Center for Cancer Care
    Jonesboro, Arkansas 72401, United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Alta Bates Summit Medical Center
    Berkeley, California 94704, United States
  • Precision Research Institute, LLC
    Chula Vista, California 91910, United States
  • Compassionate Cancer Care Medical Group, Inc.
    Corona, California 92879, United States
  • Compassionate Care Research Group, Inc.
    Fountain Valley, California 92708, United States
  • Long Beach Memorial Medical Center
    Long Beach, California 90806, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Valley Medical Oncology Consultants
    Pleasanton, California 94588, United States
  • Emad Ibrahim, MD, Inc.
    Redlands, California 92373, United States
  • Compassionate Cancer Care Medical Group, Inc
    Riverside, California 92501, United States
  • St Joseph Heritage Healthcare Institution
    Santa Rosa, California 95403, United States
  • Wellness Oncology Hematology
    West Hills, California 91307, United States
  • Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Omega Research Consultants LLC
    DeBary, Florida 32713, United States
  • Pasco Pinellas Cancer Center
    Holiday, Florida 34691, United States
  • Lakes Research, LLC
    Miami Lakes, Florida 33014, United States
  • AMPM Research Clinic
    Miami, Florida 33133, United States
  • Mid Florida Hematology and Oncology Centers
    Orange City, Florida 32763, United States
  • Florida Cancer Research Institute
    Plantation, Florida 33324, United States
  • Bond Clinic, P.A.
    Winter Haven, Florida 33881, United States
  • John B Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Dwight D. Eisenhower Army Medical Center
    Fort Gordon, Georgia 30905, United States
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Clintell, Inc/Swedish Covenant Hospital
    Chicago, Illinois 60625, United States
  • Joliet Oncology Hematology Associates
    Joliet, Illinois 60435, United States
  • Oncology Specialists, SC
    Park Ridge, Illinois 60068, United States
  • Swedish American Cancer Center
    Rockford, Illinois 61114, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • Floyd Memorial Cancer Center of Indiana
    New Albany, Indiana 47150, United States
  • Northern Indiana Cancer Research Consortium
    Westville, Indiana 46391, United States
  • Ashland-Bellefonte Cancer Center
    Ashland, Kentucky 41101, United States
  • West Ky Hematology & Oncology Group, PSC
    Paducah, Kentucky 42003, United States
  • Pontchartrain Cancer Center
    Covington, Louisiana 70433, United States
  • Highland Clinic
    Shreveport, Louisiana 71105, United States
  • Penobscot Bay Medical Center
    Rockport, Maine 04856, United States
  • RCCA MD LLC/The Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Reliant Medical Group
    Worcester, Massachusetts 01608v, United States
  • Quest Research Institute
    Royal Oak, Michigan 48073, United States
  • Forrest General Hospital
    Hattiesburg, Mississippi 39401, United States
  • Freeman Health Systems
    Joplin, Missouri 64804, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Saint Francis Cancer Treatment Center
    Grand Island, Nebraska 68803, United States
  • Southeast Nebraska Hematology & Oncology Consultants, PC
    Lincoln, Nebraska 68510, United States
  • New Jersey Hematology Oncology Associates
    Brick, New Jersey 08724, United States
  • North Shore Hematology Oncology Associates
    East Setauket, New York 11733, United States
  • Waverly Hematology Oncology
    Cary, North Carolina 27518, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • The Lindner Research Center at the Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Mercy Health Youngstown LLC DBA
    Youngstown, Ohio 44504 44501, United States
  • Good Samaritan Hospital Corvallis
    Corvallis, Oregon 97330, United States
  • University of Pittsburgh Medical Center (UPMC)
    Pittsburgh, Pennsylvania 15232, United States
  • Associates in Hematology and Oncology, PC
    Upland, Pennsylvania 19013, United States
  • AnMed Health Cancer Center
    Anderson, South Carolina 29621, United States
  • Bon Secours Saint Francis Cancer
    Greenville, South Carolina 29607, United States
  • Carolina Blood and Cancer Care
    Rock Hill, South Carolina 29732, United States
  • Cookeville Regional Medical Center
    Cookeville, Tennessee 38501, United States
  • The West Clinic, PC, d/b/a West Cancer Center
    Germantown, Tennessee 38138, United States
  • CHI St. Joseph Health Cancer Center
    Bryan, Texas 77802, United States
  • Texas Oncology -Methodist Dallas Cancer Center
    Dallas, Texas 75203, United States
  • Oncology Consultants
    Houston, Texas 77030, United States
  • Texas Oncology, PA
    McAllen, Texas 78503, United States
  • Methodist Richardson Medical Center- Cancer Center
    Richardson, Texas 75082, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Delta Oncology Associates
    Portsmouth, Virginia 23704, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • CISSS de la Montérégie-Centre
    Greenfield Park, Quebec J4V 2H1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • CHU de Quebec - Universite Laval
    Québec, Quebec G1S 4L8, Canada
  • Cha Bundang Medical Center
    Seongnam-si, Gyeonggi-do 13496, Korea, Republic of
  • Severance Hospital
    Sinchon-dong, Seoul 03722, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2018, 24 months.

Results were first posted in Mar 2022, 4 years 1 month after primary completion. A results delay was requested in Jan 2020.

Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2015
First posted
Dec 31, 2015
StartActual
Jan 19, 2016
Primary completionActual
Jan 24, 2018
CompletionActual
Oct 31, 2018
Results delay requested
Jan 23, 2020
Results first posted
Mar 2, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02643420
Responsible party
Sponsor
First posted
Dec 31, 2015
Start date
Jan 19, 2016
Primary completion
Jan 24, 2018
Completion
Oct 31, 2018
Results posted
Mar 2, 2022
Last update
Mar 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflapegrastim · Pegfilgrastim

Start the discussion